Disclaimer: The regulatory information provided on this page reflects our understanding of Swiss federal law as of June 2026 and is intended for general informational purposes only. Cannabis-related regulations are actively evolving in Switzerland and can vary by canton. This page does not constitute legal advice. Importers and formulators are strongly encouraged to consult a qualified Swiss legal or regulatory professional before shipping.
Switzerland’s Hemp Regulatory Framework: What Terpene Buyers Need to Know
Switzerland operates one of the most permissive hemp regulatory environments in Europe, and for terpene buyers, that distinction is important.
While most EU member states cap THC content in hemp products at 0.3%, the Swiss federal threshold sits at 1.0% total THC, per the Federal Act on Narcotics and Psychotropic Substances (NarcA). Products that remain below that threshold are not classified as narcotics and may be marketed, imported, and sold freely across the country.
That 1% threshold is not incidental. It reflects over a decade of deliberate policy and has produced one of the most sophisticated CBD and hemp markets on the continent.
For formulators and procurement teams importing terpene oils from the United States, this matters at every stage of the supply chain. Unlike shipments destined for France, Sweden, or Germany, where tighter limits and inconsistent enforcement create friction, Switzerland offers predictable clearance timelines, a customs authority experienced with hemp imports, and a legal framework that does not require a special import license for compliant hemp-derived terpene oils.
What it does require is documentation, and that documentation needs to be correct.
The 1% THC Standard and How It Applies to Terpene Oils
Under the Swiss Narcotics Act, any cannabis-derived product with a total THC content at or above 1% is classified as a prohibited narcotic. Products below that threshold are considered non-psychoactive and may be marketed legally, provided they comply with the relevant product-category regulations that apply to their intended use.
Cannabis-derived terpene oils intended as scented oils or chemical inputs for formulation are subject to the Federal Chemicals Act as a catch-all classification when they do not fall under food, cosmetic, or tobacco product law.
The key compliance step for importing CDTs into Switzerland is ensuring your COA clearly reports total THC, not just Delta-9 THC, using a validated analytical method such as GC-MS or GC-FID.
Swiss authorities assess total THC content, and shipments that only report Delta-9 without accounting for THCa conversion can create clearance issues even when the product is genuinely compliant. All Terpene Belt Farms products ship with full GC-MS COAs documenting total cannabinoid content, ensuring your import documentation meets Swiss federal standards from the start.
Product-Category Rules: What Governs Different Terpene Applications
Switzerland does not regulate hemp-derived terpene products under a single statute. The governing framework depends entirely on how the product is presented and used, which means formulators working across multiple product types need to understand which regulatory body has jurisdiction over each. The Swiss Federal Council’s approach to CBD and hemp products was clarified in Swissmedic’s implementation guide on CBD-containing products, which designates the applicable authority based on end-use category.
The product-category breakdown works as follows:
- Terpene Oils Marketed as Scented Oils or Chemical Inputs: Governed by the Federal Chemicals Act and Chemical Products Ordinance. Terpene Belt Farms CDTs and standard terpene oils imported for B2B formulation fall into this category. Ready-to-use scented oils containing CBD must include a denaturant per the Swiss Chemicals Notification Authority ruling of March 2022 to prevent oral misuse; pure terpene oils without CBD are not subject to this specific requirement.
- Terpene-Containing E-Liquids for Vape Applications: As of October 1, 2024, the new Tobacco Products Act (TabPA) governs all e-cigarettes and their refill liquids in Switzerland. Hemp-derived terpene oils intended for use in vape formulations fall under this framework when marketed as or incorporated into e-liquid products. Manufacturers and importers are required to file digital product notifications via the federal Tabacinfo platform within one year of market placement.
- Terpene Applications in Food and Beverages: CBD and hemp-derived ingredients in food products are classified as novel foods under Swiss food law administered by the Federal Food Safety and Veterinary Office (FSVO). Hemp teas and infusions may be marketed without prior authorization; other CBD-containing food formats require FSVO approval. THC limits for food applications are stricter, capped at 2 mg per kilogram of product.
- Cosmetic and Topical Applications: Natural CBD derived from cannabis seeds or leaves may be used in cosmetics; cosmetic applications of terpenes are not specifically restricted provided the finished product complies with the Federal Act on Foodstuffs and Utility Articles (LMG).
| Product Type | Governing Authority | Key Requirement |
| Terpene Oils (B2B / Chemical Input) | Federal Chemicals Act | Total THC below 1%, COA required |
| E-Liquid/Vape Formulations | TabPA / Tabacinfo platform | Product notification within 1 year of placement |
| Food and Beverage Applications | FSVO / Novel Food rules | THC max 2 mg/kg in finished product |
| Cosmetic/Topical Use | LMG | Natural cannabinoid source from seeds or leaves |
| Medical Cannabis (THC above 1%) | Swissmedic / TPA | Physician prescription required; Swissmedic license for supply chain |
Medical Cannabis Access Since August 2022
Switzerland simplified medical cannabis prescribing significantly on August 1, 2022. Prior to that date, patients seeking cannabis-based medicines containing above 1% THC required a special exception permit from the Federal Office of Public Health (FOPH), a process that was time-consuming and granted to very few cases.
Since the regulatory change, physicians may now prescribe medical cannabis directly without FOPH exception authorization, while the cultivation, manufacture, and commercial distribution of medical cannabis products above the 1% threshold still require Swissmedic licensing under the Therapeutic Products Act (TPA).
For terpene suppliers, the practical implication is that the Swiss medical cannabis market is expanding, and formulators producing pharmaceutical-grade or medical-adjacent products have a growing customer base to supply.
Why Switzerland Is One of Europe’s Best Import Markets for Hemp Terpenes
Switzerland is not a European Union member state. That distinction carries significant practical advantages for US-based hemp terpene exporters.
Because Switzerland operates under its own bilateral trade agreements rather than EU harmonization directives, it is not bound by the EU’s 0.3% THC cultivation and product threshold. Swiss customs officials are experienced with hemp imports and, when documentation is properly prepared, clearance typically takes two to three business days. This is consistently faster than most EU destinations.
The Swiss market has also developed considerable infrastructure around hemp and CBD over the past decade. Distributors, formulators, and retailers are familiar with third-party tested, COA-backed product formats.
The sophistication of Swiss buyers, combined with a regulatory environment that does not require import permits for compliant hemp terpene oils, makes it one of the most accessible markets for premium US-grown terpenes entering Europe.
Documentation You Need to Clear Swiss Customs
Swiss customs officials do not require a special narcotics import license for hemp-derived terpenes that are clearly below the 1% THC threshold. What they do require is a complete, properly prepared documentation package. Missing or inconsistent documentation is the primary reason compliant shipments face delays.
The required documentation for a standard terpene oil shipment into Switzerland includes:
- Certificate of Analysis (COA): Must be from an ISO/IEC 17025-accredited laboratory and report total THC content using a validated GC-MS or GC-FID method. The COA should be current (typically within one harvest cycle) and clearly identify the product by batch number.
- Commercial Invoice: Must accurately describe the product (e.g., “hemp-derived terpene oil, cannabis essential oil”), state the THC content and the fact that it is below the 1% threshold, and include full supplier and buyer details with harmonized tariff classification codes.
- Packing List: Must match the commercial invoice exactly, including weight, unit count, and packaging format.
- Product Description or Safety Data Sheet: Helpful but not universally required; included by default with all Terpene Belt Farms shipments.
All Terpene Belt Farms products ship with complete, accredited COA documentation. Our GC-MS testing confirms total cannabinoid content and terpene composition at the batch level, giving Swiss customs the analytical verification they need to process your shipment without delays.
Swiss Import VAT and Tax Classification
Import VAT of 7.7% applies to all goods entering Switzerland at the standard rate. A reduced rate of 2.5% applies to goods qualifying as necessities, such as food.
Hemp-derived terpene oils imported as chemical or aromatic inputs are subject to the standard 7.7% rate. Importantly, a Swiss Federal Supreme Court ruling clarified that CBD products not containing tobacco are not subject to tobacco tax, which means pure hemp-derived terpene oils do not carry the additional tobacco tax burden that historically applied to some hemp products under prior Customs Authority practice.
How the Swiss Market Is Changing: Legislative Developments to Watch
Switzerland is currently on the most credible path to full recreational cannabis legalization of any European nation. That trajectory is important for any formulator or brand building a supply chain for the Swiss market today, because the regulations surrounding terpenes and cannabis in 2027 will look meaningfully different from what they are now.
The Cannabis Pilot Trials and What They Have Shown
Since 2023, Switzerland has been running government-authorized cannabis pilot trials in multiple cities, including Basel, Bern, Geneva, Zurich, and Lausanne. These are not token programs. As of mid-2025, over 10,400 adults were participating across seven active trials, with the Zurich “Züri Can” project alone recording more than 88,000 legal cannabis transactions, distributing approximately 750 kg of product to over 2,300 registered participants.
Early data from the FOPH’s published cross-trial overview indicates measurable displacement of the illicit market, no escalation in consumption rates, and a notable shift toward lower-risk consumption methods including vaporizers.
The pilot program framework allows participants to purchase five product categories: flower, hash, vapes, oils, and edibles, with THC content ranging from 5% to 20%. These are strictly controlled trials available only to registered adult Swiss residents who are existing cannabis consumers. Tourists and non-residents cannot participate.
The Cannabis Products Act Draft: What It Proposes
In February 2025, the National Council’s Social Security and Health Committee approved a preliminary draft of the Cannabis Products Act (CanPG) by a vote of 14 to 9, initiating a formal legislative process toward full adult-use legalization. The public consultation period on the full draft bill text ran from August 29 to December 1, 2025. The Federal Council is expected to present the revised bill to Parliament in 2026, with a projected window for the first legal commercial sales in late 2026 or 2027.
The key structural elements of the draft as proposed include:
- State-Regulated, Non-Profit Retail Model: Sales would occur through a limited number of licensed outlets; vertical integration between producers and retailers is explicitly prohibited.
- Home Cultivation: Adults may grow up to three female cannabis plants in the flowering phase for personal use.
- Public Possession: Adults may carry cannabis products containing up to 5 grams total THC in public.
- Product Tracking: A national seed-to-sale digital tracking system would be established, requiring full supply chain traceability.
- Advertising: Advertising of cannabis products would be strictly prohibited. Packaging must be neutral and child-resistant.
- THC-Based Taxation: A steering levy differentiated by consumption format would apply, designed to make high-THC products more expensive relative to lower-risk alternatives.
For terpene suppliers and formulation partners, the practical significance of this trajectory is supply chain readiness.
Brands entering the Swiss market now, building compliant documentation processes, establishing wholesale relationships, and validating terpene profiles against Swiss product standards, will be positioned to scale as the regulated market opens.
Terpene Belt Farms: Your Verified Shipping Partner for the Swiss Market
Supplying a market like Switzerland demands more than product quality. It requires documentation precision, consistent batch testing, and a supplier that has built its operations around traceability from the start.
Terpene Belt Farms operates out of Byron, California, where our cannabis essential oils are extracted fresh from harvest using our Fresh Never Frozen® cold-chain methodology. Every batch ships with a full GC-MS COA from an ISO/IEC 17025-accredited laboratory, confirming both terpene composition and total cannabinoid content at the batch level.
Our hemp-derived terpene oils contain no residual solvents, no synthetic additives, and no botanical blends presented as cannabis-derived. They are produced under cGMP-aligned processes with full traceability from cultivation through extraction and bottling. For Swiss importers, this means your COA is accurate, your documentation is complete, and your product will clear customs on the first attempt.
If you are a brand or formulator looking to build a terpene supply chain for the Swiss market, we can support you from sample evaluation through wholesale ordering. Our team has worked with international partners across Europe and can provide the documentation format that Swiss customs expects.
Partner with Terpene Belt Farms for wholesale supply to Switzerland. Get in touch through our wholesale portal to discuss MOQs, product selection, and documentation requirements.
Frequently Asked Questions About Buying Terpenes in Switzerland
Are Hemp-Derived Terpenes Legal to Import Into Switzerland?
Yes. Hemp-derived terpene oils with a total THC content below 1% are not classified as narcotics under Swiss federal law and do not require a special import license. They are subject to the Federal Chemicals Act when imported as B2B formulation inputs. Proper documentation, including a COA confirming total THC below 1% from an accredited laboratory, is required for customs clearance.
What Is Switzerland’s THC Limit for Hemp Products?
Switzerland permits hemp and hemp-derived products with a total THC content up to 1.0%, which is more permissive than the EU’s 0.3% standard. This applies to hemp flowers, scented oils, terpene oils, and other CBD-containing products. Products at or above 1% THC are classified as prohibited narcotics under the Federal Narcotics Act, except when prescribed as medical cannabis.
Do I Need a Swissmedic License to Import Terpene Oils?
No, not for compliant hemp-derived terpene oils below the 1% THC threshold. Swissmedic licensing is required for the cultivation, manufacture, and commercial supply chain of medical cannabis products above 1% THC. CDTs and hemp-derived terpene oils imported as chemical or aromatic inputs for B2B formulation do not fall under Swissmedic’s scope.
How Long Does Swiss Customs Clearance Take for Hemp Terpene Shipments?
When documentation is properly prepared, and the product is clearly below the 1% THC threshold, Swiss customs clearance typically takes two to three business days. Switzerland’s customs authority is experienced with hemp imports and processes compliant shipments efficiently. Delays are almost always documentation-related, not product-related.
What Changed for Vape and E-Liquid Products in 2024?
Switzerland’s new Tobacco Products Act (TabPA) came into force on October 1, 2024. Under this framework, hemp-containing products marketed as plant-based smoking products, e-liquids, or vape cartridges are now regulated under tobacco product law rather than food law. Manufacturers and importers must file digital product notifications via the federal Tabacinfo platform within one year of market placement. The 1% THC limit continues to apply.
What Is the Cannabis Products Act and Does It Affect Terpene Imports?
The Cannabis Products Act (CanPG) is a draft federal law approved by Switzerland’s National Council Health Committee in February 2025 that proposes to legalize adult-use cannabis under a state-regulated model. It is not yet in force and is currently moving through the full parliamentary process. If enacted as drafted, it would create a regulated commercial market for THC cannabis products, which could significantly expand the market for terpene formulation inputs in Switzerland. The CanPG does not change current rules for hemp-derived terpene imports.
Can I Order Terpene Samples Before Committing to Wholesale Volume?
Yes. Terpene Belt Farms offers sample kits specifically designed for R&D evaluation. Each kit ships with full COA documentation, making it straightforward to assess terpene profile and verify compliance documentation before moving to wholesale volume.
Sources for this Article
- Fedlex: “Federal Act on Narcotics and Psychotropic Substances (Narcotics Act, NarcA) of 3 October 1951” – fedlex.admin.ch/eli/cc/1952/241_241_245/en
- Swissmedic: “Products containing cannabidiol (CBD) – overview” – swissmedic.ch/swissmedic/en/home/news/mitteilungen/products-containing-cannabidiol–cbd—overview.html
- Fedlex: “Federal Act on Protection against Dangerous Substances and Preparations (Chemicals Act, ChemA) of 15 December 2000” – fedlex.admin.ch/eli/cc/2004/724/en
- Baker McKenzie InsightPlus: “Switzerland: Revision of tobacco products legislation” – insightplus.bakermckenzie.com/bm/consumer-goods-retail_1/switzerland-revision-of-tobacco-products-legislation
- Fedlex: “Federal Act on Medicinal Products and Medical Devices (Therapeutic Products Act, TPA) of 15 December 2000” – fedlex.admin.ch/eli/cc/2001/422/en
- Loyens & Loeff: “Swiss indirect tax implications for importing CBD products (THC < 1%)” – loyensloeff.com/insights/news–events/news/swiss-indirect-tax-implications-for-importing-cbd-products-thc–1-/
- International Journal of Drug Policy: “” – sciencedirect.com/science/article/pii/S0955395924002949
- Chambers and Partners: “Medical Cannabis & Psychedelic Medicines 2026 – Switzerland” – practiceguides.chambers.com/practice-guides/medical-cannabis-psychedelic-medicines-2026/switzerland/trends-and-developments
